ESK981

Phase 2Small molecule

UUniversity of Michigan Rogel Cancer Center

ESK981 is one of 69 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

ESK981

UUniversity of Michigan Rogel Cancer Center

Phase 2

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Ifex

BBaxter Healthcare Corporation

Preclinical

—8

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Solid Tumors

NCT05988918

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT03456804·13 enrolled

Solid Tumors1 trial

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT05988918·66 enrolled

Renal Cell Carcinoma1 trial

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03562507·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ESK981. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ESK981 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ESK981. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Michigan Rogel Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Michigan Rogel Cancer Center

ESK981

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Prostate Cancer1 trial

Solid Tumors1 trial

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News